Posted by dytekllc on Nov 14, 2011
Research Associate Professor
Scientific Director, Marian S. Ware Alzheimer and Benaroya Parkinson’s Disease Drug Discovery Programs
Dr. Burnden’s proposal is close behind Puglieli’s in terms of proximity to animal model testing, after Brunden does some toxicology. Brudens proposal focuses on a family of aminothienopyridizine (ATPZs) compounds that emerged from 290,000 compound screens for drugs to block tangle formation in AD. He has identified several ATPZs that are worthy of bringing forward in animal studies.